Intravenous temozolomide approved in the US and EU
This article was originally published in Scrip
Executive Summary
Schering-Plough announced on March 5th that the anticancer temozolomide had been approved for marketing in an intravenous formulation in the US and the EU. It is currently marketed in an oral formulation, as Temodar in the US and Temodal in the EU.